

Dear Manufacturers,

I am writing on behalf of Citizens Memorial Hospital District (340B ID# DSH260195) to inform manufacturers that Citizens Memorial Hospital District recently underwent an audit by the Health Resources and Services Administration (HRSA) of Citizens Memorial Hospital District's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, Citizens Memorial Hospital District qualified for the 340B Program as a disproportionate share hospital located in Bolivar, Missouri and has participated in the 340B Program since September 9, 2005.

Through the audit process, Citizens Memorial Hospital District was found to have non-compliance within their 340B Program and responsible for repayment as a result of the following finding(s):

CMH dispensed a 340B drug to an ineligible individual, as prohibited by 42 USC 256b(a)(5)(B). In the course of investigating this particular instance, we discovered that we had not in fact claimed 340B pricing on the drug dispensed to this individual. Thus, no repayment is owed for this particular transaction. However, we are in the process of reviewing all drugs dispensed during the audit period and up to the present time, to determine if there were in fact any 340B drugs dispensed to ineligible individuals.

If during its ongoing review of drugs dispensed Citizens Memorial Hospital District discovers any drugs dispensed to ineligible individuals, Citizens Memorial Hospital District will identify all affected manufacturers and will contact each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from Citizens Memorial Hospital District and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact Tim Wolters, Director of Reimbursement, Citizens Memorial Hospital, 1500 North Oakland, Bolivar, MO 65613, or call 417-328-7286.

Sincerely,

Donald J. Babb
Chief Executive Officer